

Press Release



ASKA Pharmaceutical Obtains the Additional Approval of an Indication of FREWELL® COMBINATION TABLETS LD/ULD “ASKA” for the Infertility Treatment

TOKYO, December 28, 2022 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi), announced that its dysmenorrhea agent, FREWELL COMBINATION TABLETS LD/ULD “ASKA” (generic name: norethisterone/ethinylestradiol) has been additionally covered by insurance for the infertility treatment, effective December 28, 2022.

The efficacy and safety of this drug for “adjusting the timing of initiation of regulated ovarian stimulation in assisted reproductive technology” have been evaluated as the medical and pharmaceutical public knowledge based on the findings of domestic usage surveys and domestic and foreign clinical practice guidelines.

ASKA will further contribute to assisted reproductive medicine in the infertility treatment by offering a new option with this drug.

Summary of additional approval

*The underlined items below are the contents of approval.

Product name	FREWELL® COMBINATION TABLETS LD/ULD “ASKA”
Generic name	Norethisterone/ethinylestradiol
(Indications)	(Dysmenorrhea)
Dosage and administration	Take 1 tablet a day orally at a fixed time every day for 21 days, followed by a 7-day rest period. The cycle should be 28 days, and the next cycle of tablets should be taken from the 29th day, regardless of whether bleeding has ended or not, and the cycle should be repeated in the same manner thereafter. <u>(Adjusting the timing of initiation of regulated ovarian stimulation in assisted reproductive technology)</u> <u>Take 1 tablet a day orally at a fixed time, in general for 14-21 days</u>
Coverage start date	December 28, 2022

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp